Skip to content

Author

Ali Hanbashi

We have 2 of 39 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Isorhamnetin Reverses Doxorubicin Resistance in MCF-7/Doxo Cells by Suppressing P-glycoprotein-mediated Drug Efflux and Reactivating Apoptosis

Doxorubicin resistance is a major challenge in breast cancer treatment, leading to cancer recurrence and poor therapeutic outcomes. Therefore, new agents that can overcome chemoresistance are urgently needed. Chemotherapy is widely used as a frontline treatment for breast cancer (BC), but chemoresistance to...

Abdulmajeed M. Jali, Ali Hanbashi, F. Kamli et al. · 0 citations
Sep 2026

Integrated Transcriptomic, Network Pharmacology, and Machine-Learning Framework Identifies Candidate Phytochemical-Associated Targets in Lung Adenocarcinoma

CA4 is prioritized as a reproducible LUAD-associated candidate supported by transcriptomic, machine-learning, immune, survival, and docking evidence, but the computational findings do not demonstrate direct phytochemical regulation of CA4 or therapeutic efficacy.

Awaji Y. Safhi, Fahad Y. Sabei, Ali Hanbashi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.